Mizuho analyst Joseph Catanzaro raised the firm’s price target on Tango Therapeutics (TNGX) to $30 from $20 and keeps an Outperform rating on the shares post the Q1 report. The firm cites increased front-line pancreatic ductal adenocarcinoma revenue assumptions for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Piper Sandler cuts Tango Therapeutics Neutral following Q1 report
- Tango Therapeutics price target raised to $55 from $28 at Leerink
- Tango Therapeutics price target raised to $33 from $19 at Wedbush
- Tango Therapeutics downgraded to Hold from Buy at Jefferies